ORPHA Strategy Consulting’s David Schwicker offered three different perspectives involving real-world evidence and adaptive pathways in a write up published on PharmExec.Com.
Schwicker spotlights a three-person panel during ISPOR’s 2017 Annual European Congress in the U.K. which included the perspectives of patients, payers and the biopharmaceutical industry regarding adaptive pathways and real-world evidence.
The panel included:
- European Patients’ Forum and Co-Founder Secretary General Nicola Bedlington;
- National Health Care Institute International Department Head Ad Schuurman; and
- Takeda Senior Director Rob Thwaites.
To read more on what they discussed during the debate, click here.